VIVOS THERAPEUTICS INC: FILES FOR NON-TIMELY 10-Q WITH U.S. SEC
VIVOS THERAPEUTICS INC -ANTICIPATES THAT ITS REVENUE INCREASED BY OVER 50% FOR THREE MONTHS ENDED SEPTEMBER 30
VIVOS THERAPEUTICS INC -ANTICIPATES INCREASE IN ITS NET LOSS FOR THREE MONTHS ENDED SEPTEMBER 30, 2025 VERSUS THREE MONTHS ENDED SEPT 30, 2024
Source text: [ID:n0001493152-25-023404]
Further company coverage: VVOS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.